+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Filgrastim Biosimilars Global Market Opportunities and Strategies to 2030: COVID-19 Implications and Growth

  • ID: 5232529
  • Report
  • December 2020
  • Region: Global
  • 266 pages
  • The Business Research Company
1 of 5

FEATURED COMPANIES

  • Biocon Limited
  • Dr. Reddy's Laboratories
  • Intas Biopharmaceuticals
  • Novartis International AG
  • MORE
Filgrastim Biosimilars Global Market Opportunities and Strategies to 2030: COVID 19 Implications and Growth provides the strategists, marketers and senior management with the critical information they need to assess the global Filgrastim Biosimilars market.

Reasons to Purchase
  • Outperform competitors using accurate up to date demand-side dynamics information.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Identify growth segments for investment.
  • Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
  • Create regional and country strategies on the basis of local data and analysis.
  • Stay abreast of the latest customer and market research findings
  • Benchmark performance against key competitors.
  • Develop strategies based on likely future developments.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Gain a global perspective on the development of the market.
Description:

Where is the largest and fastest growing market for the Filgrastim Biosimilars market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The global Filgrastim Biosimilars market opportunities and strategies to 2030 report answers all these questions and many more.

The report covers the following chapters
  • Executive Summary - The executive summary section of the report gives a brief overview and summary of the report
  • Report Structure - This section gives the structure of the report and the information covered in the various sections.
  • Introduction - The introduction section of the report gives brief introduction about segmentation by geography, segmentation by game type, and by device.
  • Market Characteristics - The market characteristics section of the report defines and explains the filgrastim biosimilars market. This chapter also defines and describes goods and related services covered in the report.
  • Trends and Strategies - This chapter describes the major trends shaping the global filgrastim biosimilars market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
COVID Impact Analysis - This section provides an insight on how the pandemic is impacting the filgrastim biosimilars market.
  • Global Market Size and Growth - This section contains the global historic (2015-2019) and forecast (2019-2023), (2023-2025), and (2025-2030) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
  • Regional Analysis - This section contains the historic (2015-2019) and forecast (2019-2023), (2023-2025), and (2025-2030) market values and growth and market share comparison by region.
  • Segmentation - This section contains the market values (2015-2030) and analysis for different segments.
  • Regional Market Size and Growth - This section contains the region’s market size (2019), historic (2015-2019) and forecast (2019-2023), (2023-2025), and (2025-2030) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, South America, Middle East and Africa and major countries within each region. The market overview sections of the report describe the current size of the market, background information, government initiatives, regulations, regulatory bodies, associations, corporate tax structure, investments, and major companies.
  • Competitive Landscape - This section covers details on the competitive landscape of the global filgrastim biosimilars market, estimated market shares and company profiles for the leading players.
  • Key Mergers and Acquisitions - This chapter gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
  • Market Opportunities and Strategies - This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
  • Conclusions and Recommendations - This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for filgrastim biosimilars companies in terms of product offerings, geographic expansion, marketing strategies and target groups.
  • Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered: The global filgrastim biosimilars market is segmented by -
  • By Application: Oncology; Chronic and Autoimmune Diseases; Blood Disorders; Growth Hormone Deficiency; Others
  • By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Companies Mentioned: Teva Pharmaceutical Industries Ltd.; Novartis International AG; Biocon Limited; Intas Biopharmaceuticals; Dr. Reddy's Laboratories

Countries: China, Japan, India, Australia, Indonesia, South Korea, USA, Brazil, UK, Germany, France, Russia.

Regions: Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Time series: Five years historic and forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biocon Limited
  • Dr. Reddy's Laboratories
  • Intas Biopharmaceuticals
  • Novartis International AG
  • MORE
1. Filgrastim Biosimilars Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction
6.1.1. Segmentation by Geography
6.1.2. Segmentation by Application
6.1.3. Segmentation by Distribution Channel

7. Filgrastim Biosimilars Market Characteristics
7.1. Market Definition
7.2. Market Segmentation by Application
7.2.1. Oncology
7.2.2. Chronic and Autoimmune Diseases
7.2.3. Blood Disorders
7.2.4. Growth Hormone Deficiency
7.2.5. Others
7.3. Market Segmentation by Distribution Channel
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies

8. Filgrastim Biosimilars Market Trends and Strategies
8.1. Shift Towards Development of Biosimilars
8.2. Demand For Biosimilars in The Treatment of Neutropenia
8.3. Revised FDA Regulations To Facilitate Biosimilar Drug Development
8.4. Higher Investments
8.5. Growing Mergers and Acquisitions

9. COVID-19 Impact On The Filgrastim Biosimilars Market

10. Global Filgrastim Biosimilars Market Size and Growth
10.1. Market Size
10.2. Historic Market Growth, 2015-2019, Value ($ Million)
10.2.1. Drivers of The Market 2015-2019
10.2.2. Restraints On The Market 2015-2019
10.3. Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
10.3.1. Drivers of The Market 2019-2023
10.3.2. Restraints On The Market 2019-2023

11. Global Filgrastim Biosimilars Market Segmentation
11.1. Global Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
11.1.1. Oncology
11.1.2. Chronic and Autoimmune Diseases
11.1.3. Blood Disorders
11.1.4. Others
11.1.5. Growth Hormone Deficiency
11.2. Global Filgrastim Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
11.2.1. Hospital Pharmacy
11.2.2. Retail Pharmacy
11.2.3. Online Pharmacy

12. Filgrastim Biosimilars Market, Regional and Country Analysis
12.1. Global Filgrastim Biosimilars Market, by Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
12.2. Global Filgrastim Biosimilars Market, by Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)

13. Asia-Pacific Filgrastim Biosimilars Market
13.1. Asia-Pacific Filgrastim Biosimilars Market Overview
13.2. Asia Pacific Filgrastim Biosimilars Market Overview
13.2.1. Region Information
13.2.2. Impact of COVID-19
13.2.3. Market Information
13.2.4. Background Information
13.2.5. Government Initiatives
13.2.6. Regulations
13.2.7. Regulatory Bodies
13.2.8. Major Associations
13.2.9. Corporate Tax Structure
13.2.10. Investments
13.2.11. Major Companies
13.3. Asia-Pacific Filgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
13.4. Asia-Pacific Filgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
13.5. Asia-Pacific Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.6. Asia-Pacific Filgrastim Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.7. Asia-Pacific Filgrastim Biosimilars Market: Country Analysis
13.8. China Filgrastim Biosimilars Market
13.9. China Filgrastim Biosimilars Market Overview
13.9.1. Country Information
13.9.2. Impact of COVID-19
13.9.3. Market Information
13.9.4. Background Information
13.9.5. Government Initiatives
13.9.6. Regulations
13.9.7. Regulatory Bodies
13.9.8. Major Associations
13.9.9. Corporate Tax Structure
13.9.10. Investments
13.9.11. Major Companies
13.10. China Filgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
13.11. China Filgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
13.12. China Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.13. China Filgrastim Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.14. India Filgrastim Biosimilars Market
13.15. India Filgrastim Biosimilars Market Overview
13.15.1. Country Information
13.15.2. Impact of COVID-19
13.15.3. Market Information
13.15.4. Background Information
13.15.5. Government Initiatives
13.15.6. Regulations
13.15.7. Regulatory Bodies
13.15.8. Major Associations
13.15.9. Corporate Tax Structure
13.15.10. Investments
13.15.11. Major Companies
13.16. India Filgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
13.17. India Filgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
13.18. India Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.19. India Filgrastim Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.20. Japan Filgrastim Biosimilars Market
13.21. Japan Filgrastim Biosimilars Market Overview
13.21.1. Country Information
13.21.2. Impact of COVID-19
13.21.3. Market Information
13.21.4. Background Information
13.21.5. Government Initiatives
13.21.6. Regulations
13.21.7. Regulatory Bodies
13.21.8. Major Associations
13.21.9. Corporate Tax Structure
13.21.10. Investments
13.21.11. Major Companies
13.22. Japan Filgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
13.23. Japan Filgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
13.24. Japan Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.25. Japan Filgrastim Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.26. Australia Filgrastim Biosimilars Market
13.27. Australia Filgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
13.28. Australia Filgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
13.29. Australia Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.30. Australia Filgrastim Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.31. Indonesia Filgrastim Biosimilars Market
13.32. Indonesia Filgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
13.33. Indonesia Filgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
13.34. Indonesia Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.35. Indonesia Filgrastim Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.36. South Korea Filgrastim Biosimilars Market
13.37. South Korea Filgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
13.38. South Korea Filgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
13.39. South Korea Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.40. South Korea Filgrastim Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)

14. Western Europe Filgrastim Biosimilars Market
14.1. Western Europe Filgrastim Biosimilars Market Overview
14.1.1. Region Information
14.1.2. Impact of COVID-19
14.1.3. Market Information
14.1.4. Background Information
14.1.5. Government Initiatives
14.1.6. Regulations
14.1.7. Regulatory Bodies
14.1.8. Major Associations
14.1.9. Taxes Levied
14.1.10. Corporate Tax Structure
14.1.11. Investments
14.1.12. Major Companies
14.2. Western Europe Filgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
14.3. Western Europe Filgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
14.4. Western Europe Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
14.5. Western Europe Filgrastim Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
14.6. Western Europe Filgrastim Biosimilars Market: Country Analysis
14.7. UK Filgrastim Biosimilars Market
14.8. UK Filgrastim Biosimilars Market Overview
14.8.1. Country Information
14.8.2. Impact of COVID-19
14.8.3. Market Information
14.8.4. Background Information
14.8.5. Government Initiatives
14.8.6. Regulations
14.8.7. Regulatory Bodies
14.8.8. Major Associations
14.8.9. Taxes Levied
14.8.10. Corporate Tax Structure
14.8.11. Investments
14.8.12. Major Companies
14.9. UK Filgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
14.10. UK Filgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
14.11. UK Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
14.12. UK Filgrastim Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
14.13. Germany Filgrastim Biosimilars Market
14.14. Germany Filgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
14.15. Germany Filgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
14.16. Germany Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
14.17. Germany Filgrastim Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
14.18. France Filgrastim Biosimilars Market
14.19. France Filgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
14.20. France Filgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
14.21. France Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
14.22. France Filgrastim Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)

15. Eastern Europe Filgrastim Biosimilars Market
15.1. Eastern Europe Filgrastim Biosimilars Market Overview
15.1.1. Region Information
15.1.2. Impact of COVID-19
15.1.3. Market Information
15.1.4. Background Information
15.1.5. Government Initiatives
15.1.6. Regulations
15.1.7. Regulatory Bodies
15.1.8. Major Associations
15.1.9. Taxes Levied
15.1.10. Corporate Tax Structure
15.1.11. Investments
15.1.12. Major Companies
15.2. Eastern Europe Filgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
15.3. Eastern Europe Filgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
15.4. Eastern Europe Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
15.5. Eastern Europe Filgrastim Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
15.6. Eastern Europe Filgrastim Biosimilars Market: Country Analysis
15.7. Russia Filgrastim Biosimilars Market
15.8. Russia Filgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
15.9. Russia Filgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
15.10. Russia Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
15.11. Russia Filgrastim Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)

16. North America Filgrastim Biosimilars Market
16.1. North America Filgrastim Biosimilars Market Overview
16.1.1. Region Information
16.1.2. Impact of COVID-19
16.1.3. Market Information
16.1.4. Background Information
16.1.5. Government Initiatives
16.1.6. Regulations
16.1.7. Regulatory Bodies
16.1.8. Major Associations
16.1.9. Taxes Levied
16.1.10. Corporate Tax Structure
16.1.11. Investments
16.1.12. Major Companies
16.2. North America Filgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
16.3. North America Filgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
16.4. North America Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
16.5. North America Filgrastim Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
16.6. North America Filgrastim Biosimilars Market: Country Analysis
16.7. USA Filgrastim Biosimilars Market
16.8. USA Filgrastim Biosimilars Market Overview
16.8.1. Country Information
16.8.2. Impact of COVID-19
16.8.3. Market Information
16.8.4. Background Information
16.8.5. Government Initiatives
16.8.6. Regulations
16.8.7. Regulatory Bodies
16.8.8. Major Associations
16.8.9. Taxes Levied
16.8.10. Corporate Tax Structure
16.8.11. Investments
16.8.12. Major Companies
16.9. USA Filgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
16.10. USA Filgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
16.11. USA Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
16.12. USA Filgrastim Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)

17. South America Filgrastim Biosimilars Market
17.1. South America Filgrastim Biosimilars Market Overview
17.1.1. Region Information
17.1.2. Impact of COVID-19
17.1.3. Market Information
17.1.4. Background Information
17.1.5. Government Initiatives
17.1.6. Regulations
17.1.7. Regulatory Bodies
17.1.8. Major Associations
17.1.9. Taxes Levied
17.1.10. Corporate Tax Structure
17.1.11. Major Companies
17.2. South America Filgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
17.3. South America Filgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
17.4. South America Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
17.5. South America Filgrastim Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
17.6. South America Filgrastim Biosimilars Market: Country Analysis
17.7. Brazil Filgrastim Biosimilars Market
17.8. Brazil Filgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
17.9. Brazil Filgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
17.10. Brazil Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
17.11. Brazil Filgrastim Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)

18. Middle East Filgrastim Biosimilars Market
18.1. Middle East Filgrastim Biosimilars Market Overview
18.1.1. Region Information
18.1.2. Impact of COVID-19
18.1.3. Market Information
18.1.4. Background Information
18.1.5. Government Initiatives
18.1.6. Regulations
18.1.7. Regulatory Bodies
18.1.8. Major Associations
18.1.9. Taxes Levied
18.1.10. Corporate Tax Structure
18.1.11. Investments
18.1.12. Major Companies
18.2. Middle East Filgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
18.3. Middle East Filgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
18.4. Middle East Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
18.5. Middle East Filgrastim Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)

19. Africa Filgrastim Biosimilars Market
19.1. Africa Filgrastim Biosimilars Market Overview
19.1.1. Region Information
19.1.2. Impact of COVID-19
19.1.3. Market Information
19.1.4. Background Information
19.1.5. Government Initiatives
19.1.6. Regulations
19.1.7. Regulatory Bodies
19.1.8. Major Associations
19.1.9. Taxes Levied
19.1.10. Corporate Tax Structure
19.1.11. Major Companies
19.2. Africa Filgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
19.3. Africa Filgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
19.4. Africa Filgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
19.5. Africa Filgrastim Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)

20. Global Filgrastim Biosimilars Market Competitive Landscape
20.1. Company Profiles
20.2. Teva Pharmaceutical Industries Ltd.
20.2.1. Company Overview
20.2.2. Products and Services
20.2.3. Business Strategy
20.2.4. Financial Overview
20.3. Novartis International AG
20.3.1. Company Overview
20.3.2. Products and Services
20.3.3. Business Strategy
20.3.4. Financial Overview
20.4. Biocon Limited
20.4.1. Company Overview
20.4.2. Products and Services
20.4.3. Business Strategy
20.4.4. Financial Overview
20.5. Intas Biopharmaceuticals
20.5.1. Company Overview
20.5.2. Products and Services
20.5.3. Business Strategy
20.5.4. Financial Overview
20.6. Dr. Reddy's Laboratories
20.6.1. Company Overview
20.6.2. Products and Services
20.6.3. Business Strategy
20.6.4. Financial Overview

21. Key Mergers and Acquisitions in The Filgrastim Biosimilars Market
21.1. Biocon Biologics Signs Licensing Agreement With Evotec
21.2. Samsung Bioepis Enters Into An Agreement With C-Bridge Capital
21.3. Kashiv Pharma Acquired Adello Biologics
21.4. Amneal Pharmaceuticals Merge With Impax Laboratories
21.5. Biocon Merged With Sandoz

22. Filgrastim Biosimilars Market Opportunities and Strategies
22.1. Global Filgrastim Biosimilars Market in 2023 - Countries Offering Most New Opportunities
22.2. Global Filgrastim Biosimilars Market in 2023 - Segments Offering Most New Opportunities
22.3. Global Filgrastim Biosimilars Market in 2023 - Growth Strategies
22.3.1. Market Trend Based Strategies
22.3.2. Competitor Strategies

23. Filgrastim Biosimilars Market, Conclusions and Recommendations
23.1. Conclusions
23.2. Recommendations
23.2.1. Product
23.2.2. Place
23.2.3. Price
23.2.4. Promotion
23.2.5. People

24. Appendix
24.1. Market Data Sources
24.2. Research Methodology
24.3. Currencies
24.4. Research Inquiries
24.5. About the Publisher
24.6. Copyright and Disclaimer
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Biocon Limited
  • Dr. Reddy's Laboratories
  • Intas Biopharmaceuticals
  • Novartis International AG
  • MORE
The filgrastim biosimilars market consists of sales of filgrastim biosimilars by entities (organizations, sole traders and partnerships) that manufacture filgrastim biosimilars. Filgrastim biosimilar treatment is used to stimulate the bone marrow to produce more neutrophils (white blood cells) to fight infection in patients undergoing chemotherapy for cancer treatment. The drugs may also be used to increase the number of hematopoietic stem cells in the blood before collection for use in hematopoietic stem cell transplantation. Filgrastim treatment may also be used for treating other diseases such as chronic and autoimmune diseases, growth hormone deficiency and infectious diseases.

The global filgrastim biosimilars market reached a value of nearly $785.33 million in 2019, having increased at a compound annual growth rate (CAGR) of 12.13% since 2015. The market is expected to grow from $785.33 million in 2019 to $860.12 million in 2023 at a rate of 2.30%. The growth is mainly due to the patent expiration of filgrastim biologics and government initiatives. The market is expected to grow from $860.12 million in 2023 to $984.23 million in 2025 at a CAGR of 6.97%. The market is expected to grow and reach $1,279.86 million in 2030 with a CAGR of 5.39%.

Growth in the historic period resulted from emerging markets growth, increase in patent expiration, government initiatives, increased healthcare expenditure, low cost of biosimilars, strong pipeline of drugs and increase in biopharmaceutical R&D expenditure. This growth was restricted by low number of drug approvals and lack of awareness on biosimilars among primary care physicians and specialists.

Going forward, aging population, increase in healthcare access, and rising prevalence of chronic diseases are expected to drive the market. Rise of pegfilgrastim, stringent regulations related to biosimilar approvals, prolonged production and approval times and impact of COVID-19 are major factors that could hinder the growth of the filgrastim biosimilars market in the future.

The filgrastim biosimilars market is segmented by application into oncology, chronic and autoimmune diseases, blood disorders, growth hormone deficiency, and others. The oncology was the largest segment of the filgrastim biosimilars market by application, accounting for 61.3% of the total market in 2019. Going forward, oncology is expected to be the fastest growing segment in the filgrastim biosimilars market, at a CAGR of 6.0%.

The filgrastim biosimilars market is also segmented by distribution channel into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies was the largest segment of the filgrastim biosimilars market by type, accounting for 91.7% of the total market in 2019. Going forward, the retail pharmacies segment is expected to be the fastest growing segment in the filgrastim biosimilars market, at a CAGR of 16.7%.

Western Europe was the largest region in the global filgrastim biosimilars market, accounting for 47.3% of the total in 2019. It was followed by the North America, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the filgrastim biosimilars market will be Asia Pacific and Middle East, where growth will be at CAGRs of 15.4% and 14.4% respectively. These will be followed by South America and Eastern Europe, where the markets are expected to register CAGRs of 12.5% and 9.6% respectively.

The filgrastim biosimilars market is highly concentrated, with a small number of large players in the market. The top ten competitors in the market constituting more than 98% of the total market in 2019. Major players in the market include Teva Pharmaceutical Industries, Novartis International AG, Biocon Limited, Intas Biopharmaceuticals and Dr. Reddy’s Laboratories.

The top opportunities in the filgrastim biosimilars market segmented by application will arise in the oncology segment, which will gain $57.5 million of global annual sales by 2023. The top opportunities in the filgrastim biosimilars market segmented by distribution channel will arise in the online pharmacies segment, which will gain $49.1 million of global annual sales by 2023. The filgrastim biosimilars market size will gain the most in the USA at $21.9 million.

Market-trend-based strategies for the filgrastim biosimilars market includes investing extensively in R&D activities for the development of effective and innovative biosimilars, production of biosimilars for neutropenia treatment to improve revenues and increasing their focus on M&A growth strategies. Player-adopted strategies in the filgrastim biosimilars market include investing in expanding operations through innovative product launches, strategic partnerships, acquisitions and mergers to strengthen their service offerings.

To take advantage of the opportunities, the publisher recommends the filgrastim biosimilars market companies to focus on a strategic partnerships, focus on research & development, focus on the production of biosimilars for neutropenia treatment, expand in emerging markets, leverage e-commerce to maximize reach and revenues, leverage online pharmacies, set up authorized distributors and sales representatives, provide competitively priced offerings in low-income countries to reach new users companies, focus on creating awareness, participate in trade shows and events and focus on creating awareness among patients and doctors.
Note: Product cover images may vary from those shown
4 of 5
  • Teva Pharmaceutical Industries Ltd.
  • Novartis International AG
  • Biocon Limited
  • Intas Biopharmaceuticals
  • Dr. Reddy's Laboratories
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll